证券日报网讯 9月29日晚间，科前生物发布公告称，根据《兽药管理条例》和《兽药注册办法》规定， 经中华人民共和国农业农村部审查，批准公司申报的猪塞内卡病毒病灭活疫苗（HB16株，悬浮培养） 为新兽药，并核发《新兽药注册证书》。 （编辑 任世碧） ...

格隆汇9月29日丨科前生物(688526.SH)公布，根据《兽药管理条例》和《兽药注册办法》规定，经中华 人民共和国农业农村部审查，批准公司申报的猪塞内卡病毒病灭活疫苗（HB16株，悬浮培养）为新兽 药，并核发《新兽药注册证书》，作用与用途：用于预防猪塞内卡病毒病。免疫产生期为二免后21日； 免疫期为6个月。 ...

Core Viewpoint - The company, Keqian Bio (688526), has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine against Porcine Seneca Valley Virus (HB16 strain) as a new veterinary drug [1] Group 1 - The approval is in accordance with the "Veterinary Drug Management Regulations" and the "Veterinary Drug Registration Measures" [1] - The company has been issued a "New Veterinary Drug Registration Certificate" for the vaccine [1]